Charles River has a long history of experience with all aspects of respiratory disease drug discovery services – from discovery of novel compounds and efficacy evaluation to safety evaluation by all clinical routes, including inhalation. Since 2005, our scientists have been named as co-inventors on nearly 70 patents for novel compounds for respiratory indications and have delivered 25 preclinical development candidates in this area.
Our portfolio of respiratory disease in vivo pharmacology models covers a number of indications, including asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Our specialists work with our partners to select the right animal model, combined with the appropriate translational biomarkers, to build a study tailored to meet the specific needs of a particular compound or discovery program.
- Asthma models
- Bacterial lung infection models
- Influenza models
- LPS-induced pulmonary neutrophilia model
- Pulmonary fibrosis models